ProBioGen selected as CMO for Asahi Kasei Pharma biologics pipeline 23rd November 2020
ProBioGen AG has completed a master service agreement with Asahi Kasei Pharma to provide high-titre cell line development and large-scale GMP manufacturing services in support of Asahi Kasei’s biologics products pipeline using its proprietary technologies, including its CHO.RiGHT cell development platform and DirectedLuck transposase technology.
ProBioGen has extensive expertise in cell line engineering, process development and GMP manufacturing of biopharmaceuticals, combining its proprietary technologies with efficient process development and robust GMP manufacturing to accelerate and advance the development of drug candidates from early concept to industrial market-readiness. ProBioGen also provides modern manufacturing solutions for viral vectors with its continuous AGE1.CR duck cell line, a vaccine platform with MVA-CR19 and provides technology support in gene therapy and vaccine development. All of the company’s services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a research-based health care innovator that discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products and is a wholly owned business unit of Asahi Kasei Corporation, a US $20 billion technology company that provides innovative, science-based solutions to a diverse range of markets including health care, chemicals and fibres, housing and construction materials and electronics.